Literature DB >> 9591791

Carbamazepine-induced pseudolymphoma with CD-30 positive cells.

D L Nathan1, D V Belsito.   

Abstract

A 44-year-old woman known to be allergic to phenytoin was treated with carbamazepine for 1 month and developed fever, lymphadenopathy, pneumonitis, hepatitis, and a morbilliform eruption. A skin biopsy specimen showed atypical lymphocytes in the dermis that were CD-3+, CD-30+, and L26-. T-cell gene rearrangement studies were negative. A diagnosis of anticonvulsant hypersensitivity syndrome with histologic features of a pseudolymphoma was made and her illness quickly improved after carbamazepine was discontinued. This case was typical of the anticonvulsant hypersensitivity syndrome and demonstrated cross-reactivity among the aromatic anticonvulsants. However, to our knowledge, this represents the first report of a carbamazepine-induced hypersensitivity with histologic features of a cutaneous pseudolymphoma, including CD-30+ cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591791     DOI: 10.1016/s0190-9622(98)70463-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

Review 1.  CD30+ Lymphoproliferative Disorders of the Skin.

Authors:  Maxwell B Sauder; John T O'Malley; Nicole R LeBoeuf
Journal:  Hematol Oncol Clin North Am       Date:  2017-04       Impact factor: 3.722

2.  Deep Sequencing of Immunoglobulin Genes Identifies a Very Low Percentage of Monoclonal B Cells in Primary Cutaneous Marginal Zone Lymphomas with CD30-Positive Hodgkin/Reed-Sternberg-like Cells.

Authors:  Arianna Di Napoli; Evelina Rogges; Niccolò Noccioli; Anna Gazzola; Gianluca Lopez; Severino Persechino; Rita Mancini; Elena Sabattini
Journal:  Diagnostics (Basel)       Date:  2022-01-24

3.  Multifocal and recurrent cutaneous pseudolymphoma associated with lamotrigine and review of the literature.

Authors:  Soroush Kazemi; Elanee Simmons; Maija Kiuru; Danielle M Tartar
Journal:  JAAD Case Rep       Date:  2022-08-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.